Proteolytic degradation of the extracellular matrix and tumor metastasis correlate with the expression of endopeptidases known as matrix metalloproteinases (MMPs). The expression of MMPs is regulated by cytokines and signal transduction pathways, including those activated by phorbol myristate acetate (PMA). We found that resveratrol, a phytoalexin present in grapes, significantly inhibits the PMA-induced increase in MMP-9 expression and activity. These effects of resveratrol are dose dependent and correlate with the suppression of MMP-9 mRNA expression levels. PMA caused about a 23-fold increase in MMP-9 promoter activity, which was suppressed by resveratrol. Transient transfection utilizing MMP-9 constructs, in which specific transcriptional factors were mutagenized, indicated that the effects of PMA and resveratrol were mediated via an activator protein-1 and nuclear factor-jB response element. Resveratrol inhibited PMA-mediated activation of c-Jun Nterminal kinase (JNK) and protein kinase C (PKC)-d activation. Therefore, we conclude that the MMP-9 inhibition activity of resveratrol and its inhibition of JNK and PKC-d may have a therapeutic potential, given that a novel means of controlling growth and invasiveness of tumors.
Introduction
Molecular mechanisms of cancer cell invasion and metastasis involve a complex series of events. One such early event involves proteolytic degradation of the extracellular matrix components (Chambers and Matrisian, 1997; Woodhouse et al., 1997) . The concept that particular protease, for example, serine proteases, cysteine proteases and matrix metalloproteinase (MMPs), contribute to invasion and metastasis, as well as tumor angiogenesis has been accepted. MMPs can be divided into four categories based on substrate preference: collagenases, gelatinases, stromelysins and membrane-associated MMPs. Among the human MMPs reported previously, gelatinase-A (MMP-2) and gelatinase-B (MMP-9) are key enzymes for degrading type IV collagen, which is a major component of the basement membrane (Zucker et al., 1993; Bernhard et al., 1994) . The expression levels of MMP-2 and MMP-9 are associated with tumor metastasis for various human cancers Sato et al., 1994) . Recent studies show a positive correlation between the expression of MMP-9 and tumor metastasis for colorectal cancer and for several types of epithelial cancer (Lee et al., 2000; Waas et al., 2002) , thus suggesting an important functional role for these proteinases in the metastasis process. The mechanisms of MMP-9 gene activation in human cancer cells are not well defined. It is known that the human MMP-9 promoter contains cis-acting regulatory elements and transcription factors, including AP-1 (À533 bp, À79 bp), NF-kB (À600 bp) and Sp1 (À588 bp), which participate in the regulation of the MMP-9 gene . MMPs are synthesized as inactive precursors and are activated by proteolytic cleavage (Nagase and Woessner, 1999; Brew et al., 2000) . Therefore, the regulation of MMPs occurs at three levels: gene expression, proenzyme processing and inhibition of enzymatic activity.
Resveratrol is a phytoalexin found in grapes and other foods that has anticancer and anti-inflammatory effects (Soleas et al., 1997a, b; Fremont, 2000) . Recently, Jang et al. (1999) demonstrated that resveratrol is a potent chemopreventive agent in assays representing the three major stages (e.g. tumor initiation, promotion and progression) of carcinogenesis. This effect has been attributed to the antioxidant activity, anti-inflammatory activity and inhibition of platelet aggregation by resveratrol (Pace-Asciak et al., 1996; Fauconneau et al., 1997) . Recently, resveratrol was found to have an MMP-2 inhibition activity in human liver myofibroblasts (Godichaud et al., 2000) . Also, resveratrol suppressed 7,12-dimethylbenzanthracene (DMBA)-induced MMP-9 expression by inhibiting NF-kB DNAbinding activity (Banerjee et al., 2002) . Although the chemopreventive function of resveratrol has been well appreciated, the mechanisms by which resveratrol exerts its MMPs inhibition effects remain largely unknown. Therefore, understanding the molecular basis of resveratrol-mediated MMP-9 regulation could lead to strategies resulting in improved cancer chemopreventive benefits.
The present study is based on a finding that resveratrol suppresses MMP-9 gene transcription. Resveratrol inhibited phorbol myristate acetate (PMA)-mediated activation of c-Jun N-terminal kinase (JNK) and protein kinase C (PKC)-d activation. These data provide a mechanistic basis for the resveratrol on the regulation of MMP-9 protease, which has a major role in tumor invasion and metastasis.
Results
Resveratrol inhibits the stimulatory effect of PMA on pro-MMP-9 release Caski cells, a human cervical cancer cell line that releases basal levels of MMP-9 when cultured in serumfree medium, were treated with various concentrations of PMA for 20 h. While the level of MMP-2 expression is not significantly altered by PMA, PMA induces the expression and secretion of large amounts of latent MMP-9 as determined by gelatin zymography (Figure 1a) . The expression and secretion of MMP-9 is induced by PMA in a dose-dependent manner, with a dramatic increase in MMP-9 activity after treatment with 75 nM PMA. As shown in Figure 1b , resveratrol decreases PMA-induced MMP-9 activity in a dosedependent manner, while the activity of a control metalloproteinase, whose size was identical to the 72 kDa type IV collagenase MMP-2 (Strongin et al., 1995) , is not reduced in resveratrol-treated cells. We assayed the conditioned medium for MMP-9 by Western blotting to exclude the presence of a physiological inhibitor such as a tissue inhibitor of metalloproteinase family members (Sato et al., 1994) (Figure 1c ). Similar to zymography data, the expression levels of MMP-9 protein gradually decrease in a dose-dependent manner, indicating that the reduced MMP-9 enzyme activity is due to smaller amounts of the protein.
Resveratrol inhibits transcription of MMP-9
The treatment of Caski cells with resveratrol also induces a decrease in the levels of PMA-stimulated MMP-9 mRNA (Figure 2a ). Reverse transcription-PCR (RT-PCR) shows that the steady-state MMP-9 mRNA levels are lower in resveratrol-treated cells compared with cells not treated with resveratrol. To investigate the relationship between MMP-9 protein expression and MMP-9 mRNA in resveratrol-treated Caski cells, we carried out time kinetic studies. As shown in Figure 2b , MMP-9 mRNA was significantly induced in cells exposed to 75 nM PMA for 12 h, but not resveratrol-treated cells. We also investigated whether resveratrol stabilized MMP-9 mRNA. Caski cells were treated with vehicle or PMA for 12 h to induce MMP-9 transcription, and then transcription was stopped with the addition of actinomycin D. RNA was isolated at different time points after treatment with actinomycin D and subjected to RT-PCR analysis. As shown in Figure 2c , treatment resveratrol did not cause a significant change in the half-life of MMP-9 mRNA. The effect of resveratrol on MMP-9 expression was additionally investigated using HEK293 cells transiently transfected with a luciferase reporter gene linked to the 0.7 kb fragment of MMP-9 promoter sequence. As shown in Figure 2d , luciferase gene expression is activated up to 23-fold in these cells treated with PMA compared with untreated cells. The treatment of cells with resveratrol (25 mM) decreases PMA-mediated luciferase activity up to twofold, indicating that the 0.7 kb fragment of the MMP-9 promoter contains resveratrol response elements. Effects of resveratrol on NF-kB and AP-1 activities AP-1 and NF-kB point-mutated MMP-9 promoters show a diminished response to treatment with PMA compared to the constructs made using a wild-type (WT) MMP-9 promoter (Figure 3a) . In subsequent experiments, cells were transiently transfected with reporter vectors that included either the AP-1-or NFkB-binding sites. Luciferase activity in the cells with the AP-1 or NF-kB construct is significantly reduced by treatment with resveratrol (Figure 3b and c). To determine whether resveratrol inhibits the activation of AP-1 and NF-kB through the inhibition of DNA binding of AP-1 and NF-kB, we examined the effect 
Resveratrol modifies the phosphorylation state of the different MAPKs activated by PMA
In the next step, we examined the activation of the different mitogen-activated protein kinase (MAPK) cascades by PMA and potential action of resveratrol. We found that the phosphorylation of JNK, which is assumed to reflect the activation of the enzyme, appears at 30 min of stimulation ( Figure 5a ). PMA-induced JNK phosphorylation was significantly inhibited by resveratrol treatment, whereas resveratrol on its own did not show any effect on the phosphorylation status of JNK. Western blot analysis with a phosphorylation-independent antibody shows that the levels of JNK protein do not change under any conditions tested (Figure 5a , lower panel). The treatment of Caski cells with PMA plus resveratrol do not alter the levels of phosphorylation of p42/p44 ERKs compared with PMA alone. Furthermore, steady-state levels of total ERK protein do not change under any conditions tested (Figure 5b ). Using an antibody that specifically recognizes phosphorylation on Thr180/Tyr182, we found that phosphorylation of endogenous p38 MAPK is induced by PMA, resveratrol and PMA plus resveratrol. Phosphorylation levels of p38 MAPK do not change regardless of conditions. Stripping the blot and incubating with a phosphorylation-state independent antibody showed that differences are not a result of changes in the level of p38 MAPK (Figure 5c ). These results indicate that resveratrol prevent PMA-mediated JNK activation signaling pathway.
Expression of dominant-negative SEK constructs inhibits the PMA-mediated stimulation of MMP-9 promoter activity JNK modulates AP-1-dependent gene expression by increasing the transactivating potential of c-Jun via phosphorylation of the amino-terminus region of this transcription factor (Minden et al., 1994a, b) . reported that AP-1 transcription factor is essentially involved in the induction of MMP-9 gene by PMA and cytokines. To obtain further evidence for JNK involvement in the stimulation of MMP-9 expression by PMA, we determined the effect of expressing either SEK (also known as JNKK1 or MKK4) or kinase-defective SEK constructs on the stimulation of plus resveratrol (50 mM) for indicated times. Equal amounts of cell lysates (40 mg) were subjected to electrophoresis and analysed by immunoblotting using phosphorylation state-specific antibodies. To ascertain that the total level of each MAPK did not change, blots were stripped and reprobed with the antibodies raised against the corresponding phosphorylation-independent MAPK MMP-9 promoter activity by PMA. HEK293 cells were cotransfected with an MMP-9 promoter construct and an expression construct encoding a kinase-defective SEK or WT SEK. Transfected cells were then treated with PMA and subsequently assayed for luciferase activity. The coexpression of an equimolar amount of the dominant-negative SEK expression construct reduced luciferase activity by 40% when compared with empty expression construct (pEBR vector). However, the expression of the SEK caused a marked 2.5-fold increase luciferase activity (Figure 6a ). To further confirm JNK involved in PMA-induced MMP-9 expression, the JNK inhibitor, SP600125, was used. The treatment with SP600125 caused a decrease in PMAinduced MMP-9 activity in a dose-dependent manner (Figure 6b ). These data suggest that an activated JNKdependent signaling module is a critical requirement for the stimulation of MMP-9 promoter activity by PMA.
Resveratrol inhibition of PMA-mediated MMP-9 expression is associated with PKC-d inactivation
To determine whether PKC activation was involved in the signal transduction pathway leading MMP-9 secretion and expression caused by PMA, the PKC inhibitor Rottlerin and Ro 31-8220 were used. The pretreatment of cells for 1 h with Rottlerin (2.5-7.5 mM) or Ro 31-8220 (2.5-7.5 mM) attenuated the PMA-induced MMP-9 expression in a concentration-dependent manner. As shown in Figure 7a , Rottlerin was more effective than Ro 31-8220 for MMP-9 downregulation. Rottlerin inhibited PKC-d fivefold more potently than other (75 nM). Conditional media were collected after 24 h followed by gelatin zymography. Gels were scanned, and then the image was inverted (clear to black and black to clear) for presentation. MMP-9 activity (band intensity) represents the mean7s.d. of at least three independent experiments. (b) Caski cells were treated with vehicle, PMA (75 nM), resveratrol (50 mM) and PMA (75 nM) plus resveratrol (50 mM) for indicated times. Equal amounts of soluble lysates (40 mg) and particulate lysates (membrane fraction) were subjected to electrophoresis and analysed by PKC isozyme-specific antibodies. A representative study is shown; two additional experiments yielded similar results. (c) HEK293 cells were transiently transfected with 1 mg of WT-MMP-9 luciferase reporter plasmid and 1 mg of expression plasmids either empty pEBR, PKC-d or dn-PKC-d. The cells were lysed and luciferase activity measured. Data represent the mean7s.d of at least three independent experiments PKC isoforms (Uddin et al., 2002) . To examine which PKC isoform was involved in the PMA-mediated effects, the expression of each PKC isoform in Caski cells was examined by Western blotting analysis. Exposure of the cells to PMA, resveratrol and PMA plus resveratrol for 30, 60 and 90 min only caused inhibition of translocation of PKC-d (but not other) isoforms from cytosol to the membrane fraction (Figure 7b) .
To further investigate PKC-d involvement in the stimulation of MMP-9 expression by PMA, we determined the effect of expressing either PKC-d or dominant-negative PKC-d (dn-PKC d) constructs on the stimulation of MMP-9 promoter activity by PMA. HEK293 cells were cotransfected with an MMP-9 promoter construct and an expression construct encoding a PKC-d or dn-PKC-d. Transfected cells were then treated with PMA and subsequently assayed for luciferase activity. The coexpression of an equimolar amount of the dn-PKC-d reduced luciferase activity by 50% when compared with empty expression construct (pEBR vector). However, the expression of the PKC-d caused a marked twofold increase luciferase activity (Figure 7c ). Taken together, these data suggest that an activated PKC-d signaling pathway is a critical requirement for the stimulation of MMP-9 expression by PMA and target for the suppression of PMA-mediated by resveratrol.
Effect of resveratrol on in vitro invasion of Caski cells
The treatment of cells with 50 mM resveratrol neither induced morphological changes nor inhibited the growth of Caski cells (data not shown). In the in vitro invasion assay, as shown in Figure 8 , resveratrol inhibited migration by more than 60%. Therefore, the effect of resveratrol on in vitro invasion inhibition was presumably correlated with its effect on MMP-9 inhibition.
Discussion
The expression of proteases such as MMP-9 is regulated by diverse growth factors, cytokines and xenobiotics such as PMA Lee et al., 2000) . Studies have shown that the mechanism responsible for PMA-mediated responses may involve direct alteration of transcription factors, but these mechanisms are not completely understood. Small molecular weight inhibitors that target the pathways that regulate MMP-9 expression could improve our understanding of these pathways and potentially be of clinical utility for the treatment of cancer. Using a cervical cancer cell line, our study demonstrates the ability of resveratrol to reduce the expression of MMP-9.
We were further interested in the inhibitory mechanism of MMP-9 expression by resveratrol. The role of MAPKs in the regulation of MMP-9 expression in malignant cells has been understood. At least two (ERK and JNK) of the three so-called mitogenic pathways known so far in mammalian cells induce upregulation of MMP-9 (Gum et al., 1997) . Recently, it has been shown that the inhibition of the p38 MAPK leads to reduced phorbol ester-induced MMP-9 expression and invasion by tumor cells (Simon et al., 1998) . To elucidate the relationship between MAPK and MMP-9 expression, we examined the effects of resveratrol to transcription factors. As Western blot analysis and RT-PCR experiments (Figures 1c and 2a) indicate that resveratrol may exert its actions through the transcriptional regulation of MMP-9. Further examination showed that the reduced activities of proteases are related to their mRNA levels. MMP-9 promoter contains AP-1-binding sites so that MAPKs pathways are important. We investigated the molecular mechanism by which resveratrol inhibits PMA-mediated expression of MMP-9 using AP-1 and NF-kB reporter constructs, and found that NF-kB and AP-1 activity are significantly reduced by treatment with resveratrol. With regard to the mechanism by which resveratrol modulates gene expression, it suppressed PMA-mediated activation of MMP-9 transcription in Caski cells by inhibiting the PKC signal transduction pathway at multiple levels. It blocked both PMA-induced translocation of PKC-d activity from cytosol to membrane. To obtain further evidence that the activation of MMP-9 induced by PMA was mediated by PKC-d, we employed Rottlerin, which has been shown to inhibit PKC-d specifically, and found that Rottlerin reverted the PMA-induced activation of MMP-9. On the other hand, the inhibition of a transiently transfected WT MMP-9 promoter by dn-PKC-d suggest that the activation of PKC-d may contribute to the expression of MMP-9 by PMA.
While our findings indicate that the ability of resveratrol to reduce MMP-9 expression is achieved via reduced PKC-d activity as well as diminished JNK activation. Indeed, the JNK pathway targets multiple transcription factors including Jun D (Cirillo et al., 1999) , ATF (Gupta et al., 1995) , and PEA (O'Hagan et al., 1996) and putative-binding sites for these DNA-binding proteins are present in the MMP-9 promoter. JNK can also increase AP-1-dependent gene expression by stimulating transcriptional activity of cJun subsequent to its phosphorylation at N-terminus transactivation domain (Minden et al., 1994a, b) . To our knowledge, this is the first report of resveratrol that inhibits MMP-9 transcriptional activation. We show that NF-kB and AP-1 is a crucial transactivator for MMP-9 gene expression, as PMA-driven luciferase activity is significantly reduced in both NF-kB and AP-1 mutant promoters. Resveratrol not only affects AP-1 and NF-kB transcription factors but also affects signal molecules such as JNK and PKC-d. Moreover, our findings indicate the efficacy of resveratrol, which selectively targets JNK without affecting the ERKs, in repressing PMA-dependent MMP-9 expression.
In conclusion, we have shown that resveratrol inhibited several essential steps of PMA-induced MMP-9 expression. First, resveratrol inhibited the activities of MMP-9. Second, this inhibition is mediated by the regulation of transcription factors such as AP-1 and NFkB. Third, resveratrol inhibited PMA-induced MMP-9 expression through the inhibition of JNK activation and PKC-d activation.
Materials and methods

Cells and materials
Human Caski cells were obtained from the American Type Culture Collection (ATCC; Rockville, MD, USA). The culture medium used throughout these experiments was Dulbecco's modified Eagle's medium, containing 10% fetal calf serum (FCS), 20 mM HEPES buffer and 100 mg/ml gentamicin. Anti-ERK, antiphospho-ERK, anti-p38, antiphospho-p38, anti-JNK and antiphospho-JNK were obtained from New England Biolabs (Beverly, MA, USA). Lipofetamine reagent was from Life Technologies (Rockville, MA, USA). Luciferase assay and b-galactosidase assay systems were from Promega (Madison, WI, USA). Resveratrol was purchased from Biomol (Plymouth Meeting, PA, USA).
Western blot analysis
Cellular lysates were prepared by suspending 1 Â 10 6 cells in 100 ml of lysis buffer (137 mM NaCl, 15 mM EGTA, 0.1 mM sodium orthovanadate, 15 mM MgCl 2 , 0.1% Triton X-100, 25 mM MOPS, 100 mM phenylmethylsulfonyl fluoride and 20 mM leupeptin), adjusted to pH 7.2. The cells were disrupted by sonication and extracted at 41C for 30 min. The proteins were electrotransferred to Immobilon-P membranes (Millipore Corporation, Bedford, MA, USA). The detection of specific proteins was carried out with an ECL Western blotting kit following the manufacturer's instructions. Subcellular fractions were prepared through following the described method. Briefly, Caski cells were incubated with vehicle, PMA (75 nM), resveratrol (50 mM), PMA plus resveratrol for 30, 60 and 90 min, then the cells were collected. The collected cells were homogenized in ice-cold homogenization buffer (20 mM Tris, 2 mM EDTA, 5 mM EGTA, 20% glycerol (v/v), 2 mM phenylmethylsulfonyl fluoride, 20 mM leupeptin, 5 mM DTT) for 20 min, then sonicated for 10 s and centrifuged at 800 g for 10 min. The supernatant (cytosolic and membrane fraction) was removed and centrifuged at 25 000 g for 15 min. The supernatant (cytosolic fraction) was obtained. The pellets (membrane fraction) were solubilized in homogenization buffer containing 0.1% NP-40. The protein levels of PKC isoforms in cytosolic and membrane fractions were determined by Western blotting analysis performed as described.
Gelatin substrate gel zymography
To determine the effect of resveratrol on PMA-induced MMP-9 activity, cells were treated with various concentrations of resveratrol in the presence of 75 nM PMA and MMP-9 expression was evaluated by zymography. Zymography was performed by the procedure described by Overall et al. (1989) with minor modification. The human cell lines were suspended in their respective media containing 10% FBS and plated at 8 Â 10 5 cells/35 mm 2 dish. Dishes were incubated until about 80% confluent, the media were aspirated and then fresh serumfree medium was added to each dish, with and without resveratrol. Supernatants were collected after incubation for 24 h. Proteins were subjected to SDS-PAGE in 10% polyacrylamide gels that were copolymerized with 1 mg/ml of gelatin. After electrophoresis, the gels were washed several times in 2.5% Triton X-100 for 1 h at room temperature to remove the SDS, then incubated for 24-48 h at 371C in buffer containing 5 mM CaCl 2 and 1 mM ZnCl 2 . The gels were stained with Coomassie blue (0.25%) for 30 min, and then destained for 1 h in a solution of acetic acid and methanol. The proteolytic activity was evidenced as clear bands (zones of gelatin degradation) against the blue background of stained gelatin.
Cloning of the human MMP-9 promoters
A 0.7 kb segment at the 5 0 -flanking region of the human MMP-9 gene was amplified by PCR using specific primers from the human MMP-9 gene (Accession No. D10051): 5 0 -ACATTTGCCCGAGCTCCTGAAG (forward/SacI) and 5 0 -AGGGGCTGCCA GAAGCTTATGGT (reverse/HindIII). The pGL2-Basic vector containing a polyadenylation signal upstream from the luciferase gene was used to construct expression vectors by subcloning PCR-amplified DNA of MMP-9 promoter into the SacI/HindIII site of the pGL2-Basic vector. Point mutations of the AP-1-and NF-kB-binding sites to the MMP-9 promoter were generated by a two-step PCR method using the following primers: AP-1-1 (5 0 -CTGACCCCTGAGTCAGCACTTG to 5 0 -CTGACCCCT-GAGTTGGCACTTG); AP-1-2 (GAAGCTGAGTCAAA-GAAGGCT to 5 0 -GAAGCTGAGTTGAAGAAGGCT); and NF-kB (CCCAGTGGAATTCCCCAGCCT to CCCAGTG-GAATTGGCCAGCCT). KpnI and HindIII sites were included in PCR products so that following KpnI and HindIII digestion of the PCR products they could be subcloned into the pGL2-Basic KpnI/HindIII site. Clones representing each point mutation were sequenced to ensure the accuracy of the PCR amplification procedure.
Plasmids, transfections and luciferase gene assays AP-1 and NF-kB reporter constructs were purchased from Clontech (Palo Alto, CA, USA). In brief, cells were plated onto six-well plates at a density of 5 Â 10 5 cells/well and grown overnight. Cells were cotransfected with 2 mg of various plasmid constructs and 1 mg of the pCMV-b-galactosidase plasmid for 5 h by the Lipofectamine method. After transfection, cells were cultured in 10% FCS medium with vehicle (DMSO) or drugs for 24 h. Luciferase and b-galactosidase activities were assayed according to the manufacturer's protocol (Promega). Luciferase activity was normalized for b-galactosidase activity in cell lysate and expressed as an average of three independent experiments.
RNA isolation and RT-PCR
To determine whether the reduced amounts of MMP-9 activity were a result of decreased levels of mRNA encoding this collagenase, we compared the levels of MMP-9 in Caski cells, which were treated with or without various concentrations of resveratrol in the presence of 75 nM PMA. MMP-9 mRNA expression was determined by RT-PCR. Total cellular RNA was extracted from Caski cells using the TRIzol reagent (Life Technologies). A cDNA was synthesized from 2 mg of total RNA using M-MLV reverse transcriptase (Gibco-BRL, Gaithersburg, MD, USA). The cDNA for MMP-9 and GAPDH were amplified by PCR with specific primers. The sequences of the sense and antisense primers for MMP-9 were: 5 0 -CACTGTCCACCCCTCAGAGC-3 0 and 5 0 -GCCACTTGTCGGCGATAAGG-3 0 , respectively. The sequences of the sense and antisense primer for GAPDH were: 5 0 -CGGACTCAACGGATTTGGTCGTAT-3 0 and 5 0 -AGCCTTCTCCATGGTTGGTGAAGA-3 0 , respectively. PCR products were analysed by agarose-gel electrophoresis and visualized by ethidium bromide.
Nuclear extract preparation and EMSA
Preparation of nuclear extracts from control or drug-treated cells were carried out as described previously (Baek et al., 2002) . The following oligonucleotides, 5 0 -CTGACCCCT-GAGTCAGCACTTG (AP-1 consensus oliginucleotide) or 5 0 -CCCAGTGGAATTCCCCAGCCT (NF-kB consensus oligonucleotide), were used as probe. The reaction mixture for EMSA contained 20 mM Tris-HCl, pH 7.6, 1 mM dithiothreitol, 2 mM MgCl 2 , 1 mM EDTA, 10% glycerol, 1% NP-40, 1 mg of poly(dI-dC) and 5 mg of nuclear proteins. Nonlabeled WT oligonucleotide was added into reaction mixture and incubated for 10 min at room temperature. 32P-labeled probe DNA (300 000 c.p.m.) was added and binding reaction was allowed to proceed for another 20 min. After reaction, mixtures were resolved on 8% polyacrylamide gels at 150 V for 4 h. Gels were dried and subjected to autoradiography.
Invasion assay
A total of 5 Â 10 4 cells/chamber were used for each invasion assay. Invasion assays were performed using modified Boyden chambers with polycarbonate nucleopore membrane (Corning, Corning, NY, USA). Precoated filters (6.5 mM in diameter, 8 mM pore-size, Matrigel 100 mg/cm 2 ) were rehydrated with 250 ml of medium, and 5 Â 10 4 cells in 200 ml medium with or without resveratrol in the presence of PMA were seeded into the upper part of each chamber. Following incubation for 24 h at 371C, nonmigratory cells on the upper surface of the filter were wiped with a cotton swab, and migrated cells on the lower surface of the filter were fixed and stained with 0.125% Comassie Blue in a methanol : acetic acid : water mixture (45 : 10 : 45 v/v/v). Random fields were counted under a light microscope.
Abbreviations MMP, matrix metalloproteinase; NF-kB, nuclear factor-kB; PMA, phorbol myristate acetate; AP, activator protein; RT-PCR, reverse transcription-PCR; WT, wild type; PKC, protein kinase C; MAPK, mitogen-activated protein kinase.
